Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.46 |
| ▸ | CCKAR | P32238 | 3/20 | 0.43 |
| ▸ | CCKBR | P32239 | 3/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13293965 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL16182631 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL12806533 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24284196 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL12287742 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24198476 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL23051891 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24899310 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL20911267 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL19243816 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | disclosed |
| US-20200283493-A1 | Novel Insulin Derivatives and the Medical Uses Hereof | NOVO NORDISK AS (DK) | 2020-09-10 | — | — | US | disclosed |
| EP-3016975-B1 | DERIVATIVES OF GLP-1 LIKE PEPTIDES, AND USES THEREOF | NOVO NORDISK AS (DK) | 2019-01-16 | — | — | EP | disclosed |
| EP-2846824-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2017-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283493-A1 | Novel Insulin Derivatives and the Medical Uses Hereof | IAPP, INSR, GPR119 | GLP1R 13/4885NOD1 2884/4885CCKAR 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.